ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Pulmonary Drug Delivery in the Era of Nanomedicine: From Biological Barriers to Artificial Intelligence-Driven Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Tea Polyphenols in the COVID-19 Era: Mechanistic Insights and Translational Challenges.Current issues in molecular biology · 2026Review
- Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC).AAPS PharmSciTech · 2026Article
- Inhalation-Based Nanoparticle Drug Delivery Targeting the Diseased Lower Airways in Idiopathic Pulmonary Fibrosis.Pharmaceutics · 2026Review
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Ferroptosis in smoke inhalation injury: from mechanisms to potential therapeutic targets.Frontiers in cell and developmental biology · 2026Review
- Nanozyme-Driven Ferroptosis-Cuproptosis Interplay in Lung Cancer.International journal of nanomedicine · 2026Review
- Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pulmonary disorders, notably highlighted by the global impact of COVID-19, continue to pose serious public health concerns with limited treatment options. To address the urgent need for effective lung-targeted therapies, strategies that maximize local therapeutic efficacy while minimizing systemic toxicity are essential to the unique anatomical location of the lungs, inhaled therapy provides a promising strategy for locally targeted drug delivery through intranasal or intratracheal administration. Integrating biomedical nanotechnology and inhaled therapy, inhaled nanoparticle drug delivery systems (INDDs) have emerged as a powerful platform capable of penetrating mucus and pulmonary surfactant barriers, enhancing lung distribution and retention, and precisely delivering small molecules, proteins, and nucleic acids in lung lesions and cells using natural or synthetic carriers. The INDDs provide a universal translational platform for structurally analogous drugs and a wide array of respiratory disorders. This review summarizes recent advances in INDDs, focusing on the critical carrier materials in formulation, performance in in vitro and in vivo, and inhalation dosage forms, highlighting design strategies to overcome lung barriers and improve clinical and preclinical therapeutic efficacy in lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.